Is Oral Ribavirin for the Treatment of Respiratory Syncytial Virus in High-risk Hematopoietic Stem Cell Transplant Recipients Really Safe?

Shilpa R. JainPakpoom PhoompoungShahid HusainUniversity Health Network University of TorontoFaculty of Medicine, Siriraj Hospital, Mahidol University2020-01-272020-01-272019-11-27Clinical Infectious Diseases. Vol.69, No.12 (2019), 2234-223515376591105848382-s2.0-85075805521https://repository.li.mahidol.ac.th/handle/20.500.14594/51299Mahidol UniversityMedicineIs Oral Ribavirin for the Treatment of Respiratory Syncytial Virus in High-risk Hematopoietic Stem Cell Transplant Recipients Really Safe?LetterSCOPUS10.1093/cid/ciz376